Early-stage
3
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
10 treatments under study, led by Gemcitabine
Research Leaders
9 sponsors active, led by The First Hospital of Jilin University
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
Research Network
Common Treatments
- Gemcitabine1
- Oxaliplatin1
- Pegaspargase1
- Durvalumab1
- Tislelizumab1
Active Sponsors
- The First Hospital of Jilin University2
- The Affiliated Hospital Of Guizhou Medical University1
- MedImmune LLC1
- Peking University Cancer Hospital & Institute1
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Top Investigators
CAMS
Chinese Academy of Medical Sciences
Related Conditions
- Highrisk Cancer1
- Extranodal Nktcell Lymphoma1
- Extranodal Nktcell Lymphoma Nasal And Nasaltype1
- Nsclc1
- Resectable1